Investor Presentation

Balance Sheet and Cash Flow ● ● Cash, and cash equivalents, including restricted cash, were $28.5 million as of 9/30/23, compared to $34.5 million as of 6/30/23. Net cash provided by continuing operations was $9.4 million, representing 5th consecutive quarter of positive cashflow from continuing operations. Capex spending was $1.7 million in the quarter, consequently, free cashflow was $7.7 million for the quarter. ● • During the third quarter $5.7 million of debt was paid down, $3.8 million of success fee in NJ, and $3 million for dispensary acquisitions in MD. 4 TERRASCEND p. 31

View entire presentation